OR WAIT null SECS
Biopharma industry faces production challenges as gene therapies move from clinical to commercialization.
The approval of the first gene therapies and technology advances have spurred research and investment for new treatments and provided hope for patients. Researchers are now talking about “cures” versus “treatments,” says Eric Langer, managing partner, BioPlan Associates, in an interview with BioPharm International. Turning clinical processes into an operational process will prove challenging.